Rates of genetic testing for women with diagnosed breast cancer appear to be increasing substantially. More than one-fourth of patients diagnosed today undergo testing,1 multiple-gene sequencing panels are replacing testing limited to BRCA1/2 mutations, and genetic counselors report ordering more tests.2 Within the next few years it is likely that most patients with newly diagnosed breast cancer will undergo genetic testing to inform their risk of developing a subsequent cancer. There is already a widening gap between the availability of more expansive genetic testing and the relative importance of results to treatment decisions.
Katz SJ, Kurian AW, Morrow M. Treatment Decision Making and Genetic Testing for Breast Cancer: Mainstreaming Mutations. JAMA. 2015;314(10):997–998. doi:10.1001/jama.2015.8088
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: